Anavex Life Sciences Releases Encouraging Long Term Data From Rett Syndrome Study

Anavex Life Sciences Corp AVXL announced that long-term clinical study results from the U.S. ANAVEX2-73-RS-001 study demonstrate a disease-modifying effect of ANAVEX2-73 (blarcamesine) for adult patients with Rett syndrome.

In the U.S. ANAVEX2-73-RS-001 trial, of all 25 patients who both started and completed the randomized, double-blind, placebo-controlled study, 24 patients voluntarily enrolled in the 12-week open-label extension (OLE) study. The 12-week extension study was subsequently further extended to 36 weeks.

The data shows that blarcamesine exhibited both symptomatic and disease-modifying effects for Rett syndrome in a clinical setting.

Continued improvement from the drug was observed from the start of the double-blind study to the end of the open-label extension part for patients continuing on blarcamesine. Patients previously on placebo who switched to blarcamesine experienced improvement.

Additionally, disease progression was also reduced with long-term treatment with blarcamesine.

Patients assigned first to blarcamesine in the double-blind part of the study and who continued during the OLE study had a statistically significant reduction in disease severity and progression compared to patients assigned first to placebo and then switched to blarcamesine.

Price Action: AVXL shares are down 1.67% at $7.95 on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechEquitiesNewsHealth CareSmall CapMarketsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!